Warner Chilcott Plc  

(Public, NASDAQ:WCRX)   Watch this stock  
Find more results for wcrx
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield 0.25/∞T
EPS 1.82
Shares 251.14M
Beta     -
Inst. own 95%

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin 17.62% 15.86%
Operating margin 21.04% 19.48%
EBITD margin - 56.04%
Return on average assets 11.16% 8.72%
Return on average equity - -
Employees 2,100 -
CDP Score - -


1 Grand Canal Square Docklands, Dublin 2
+353-1-8972000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Warner Chilcott Public Limited Company is a specialty pharmaceutical company. The Company is focused on the women�s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. The Company�s hormonal contraceptive product offerings include LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the branded product in the United States hormonal contraception market, and LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), its new oral contraceptive product, launched in January 2011, that offers women the lowest dosage of estrogen of any oral contraceptive available in the United States market. In October 2013, Actavis Inc acquired the entire share capital of Warner Chilcott PLC.